Shannon Thyme  Klinger net worth and biography

Shannon Klinger Biography and Net Worth

Insider of Moderna
A strategic, visionary leader, Ms. Klinger is driven by a deep personal and professional desire to meaningfully contribute to making the world a better place than she found it. As a breast cancer survivor, she has experienced first-hand the critical importance of creating sustainable health care systems capable of providing the right treatment for the right patient at the right time.

Ms. Klinger joined Moderna as chief legal officer on June 1, 2021. Most recently, she was chief legal officer at Novartis. Previously, she served as chief ethics, risk & compliance officer from April to May 2018, and was appointed to the Executive Committee of Novartis in this role. Before that, she was chief ethics and compliance officer and global head of litigation from 2016 to 2018. She joined Novartis in 2011 as general counsel for North America at Sandoz Inc., and later served as general counsel and global head of legal at Sandoz International from 2012 to 2016. Prior to Novartis, Ms. Klinger was a partner at Mayer Brown from 2010 to 2011, and general counsel and senior vice president at Solvay Pharmaceuticals from 2008 to 2010.

Ms. Klinger holds a juris doctor with honors from The University of North Carolina at Chapel Hill and a bachelor’s degree in psychology from the University of Notre Dame. She is a member of the State Bar of Georgia and of the District of Columbia Bar.

What is Shannon Thyme Klinger's net worth?

The estimated net worth of Shannon Thyme Klinger is at least $987,491.52 as of March 8th, 2024. Ms. Klinger owns 9,267 shares of Moderna stock worth more than $987,492 as of March 28th. This net worth estimate does not reflect any other investments that Ms. Klinger may own. Additionally, Ms. Klinger receives an annual salary of $1,760,000.00 as Insider at Moderna. Learn More about Shannon Thyme Klinger's net worth.

How old is Shannon Thyme Klinger?

Ms. Klinger is currently 53 years old. There are 6 older executives and no younger executives at Moderna. The oldest executive at Moderna is Dr. Jerh Collins Ph.D., Chief Technical Operations & Quality Officer, who is 57 years old. Learn More on Shannon Thyme Klinger's age.

What is Shannon Thyme Klinger's salary?

As the Insider of Moderna, Inc., Ms. Klinger earns $1,760,000.00 per year. There are 2 executives that earn more than Ms. Klinger. The highest earning executive at Moderna is Mr. Stephane Bancel, CEO & Director, who commands a salary of $4,970,000.00 per year. Learn More on Shannon Thyme Klinger's salary.

How do I contact Shannon Thyme Klinger?

The corporate mailing address for Ms. Klinger and other Moderna executives is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Moderna can also be reached via phone at (617) 714-6500 and via email at [email protected]. Learn More on Shannon Thyme Klinger's contact information.

Has Shannon Thyme Klinger been buying or selling shares of Moderna?

During the last quarter, Shannon Thyme Klinger has sold $117,245.10 in Moderna stock. Most recently, Shannon Thyme Klinger sold 544 shares of the business's stock in a transaction on Friday, March 8th. The shares were sold at an average price of $99.05, for a transaction totalling $53,883.20. Following the completion of the sale, the insider now directly owns 9,267 shares of the company's stock, valued at $917,896.35. Learn More on Shannon Thyme Klinger's trading history.

Who are Moderna's active insiders?

Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (CEO), W. Cornwell (Director), Arpa Garay (Insider), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Jamey Mock (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Learn More on Moderna's active insiders.

Are insiders buying or selling shares of Moderna?

During the last year, insiders at the sold shares 56 times. They sold a total of 915,065 shares worth more than $111,561,372.06. The most recent insider tranaction occured on March, 20th when Director Noubar Afeyan sold 15,000 shares worth more than $1,535,850.00. Insiders at Moderna own 15.7% of the company. Learn More about insider trades at Moderna.

Information on this page was last updated on 3/20/2024.

Shannon Thyme Klinger Insider Trading History at Moderna

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/8/2024Sell544$99.05$53,883.209,267View SEC Filing Icon  
2/29/2024Sell670$94.57$63,361.908,557View SEC Filing Icon  
12/8/2023Sell563$79.09$44,527.677,912View SEC Filing Icon  
9/8/2023Sell557$107.22$59,721.547,215View SEC Filing Icon  
9/5/2023Sell115$111.44$12,815.606,634View SEC Filing Icon  
6/2/2023Sell110$130.32$14,335.205,942View SEC Filing Icon  
3/8/2023Sell561$141.51$79,387.115,820View SEC Filing Icon  
3/2/2023Sell459$136.43$62,621.375,243View SEC Filing Icon  
9/8/2022Sell478$137.44$65,696.323,949View SEC Filing Icon  
6/8/2022Sell1,265$148.12$187,371.803,289View SEC Filing Icon  
See Full Table

Shannon Thyme Klinger Buying and Selling Activity at Moderna

This chart shows Shannon Thyme Klinger's buying and selling at Moderna by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Moderna Company Overview

Moderna logo
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $106.56
Low: $105.95
High: $112.00

50 Day Range

MA: $98.79
Low: $85.37
High: $111.98

2 Week Range

Now: $106.56
Low: $62.55
High: $163.24

Volume

3,958,501 shs

Average Volume

4,413,853 shs

Market Capitalization

$40.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6